SCHEMBL18558487

SCHEMBL18558487

CC(C)(C)N/C(=N/C(=O)c1ccc(F)cc1)Nc1cc(-c2ccc(F)cc2)n[nH]1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALPL P05186 2/20 0.42
CA12 O43570 1/20 0.42
RPA1 P27694 1/20 0.42
HDAC3 O15379 10/20 0.42
HDAC4 P56524 10/20 0.42
HDAC1 Q13547 10/20 0.42
HDAC7 Q8WUI4 10/20 0.42
HDAC2 Q92769 10/20 0.42
HDAC10 Q969S8 10/20 0.42
HDAC11 Q96DB2 10/20 0.42
HDAC8 Q9BY41 10/20 0.42
HDAC6 Q9UBN7 10/20 0.42
HDAC9 Q9UKV0 10/20 0.42
HDAC5 Q9UQL6 10/20 0.42
NCOR2 Q9Y618 5/20 0.42
ACR P10323 1/20 0.39
RAB9A P51151 2/20 0.37
ADORA3 P0DMS8 1/20 0.37
ADORA2A P29274 1/20 0.37
TP53 P04637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18558516 0.96 HDAC3 (0.39) ALPLCA12RPA1HDAC3HDAC4
SCHEMBL18558155 0.96 MAPT (0.41) ALPLCA12RPA1HDAC3HDAC4
SCHEMBL18557830 0.96 MAPT (0.41) ALPLCA12RPA1HDAC3HDAC4
SCHEMBL18558676 0.96 MAPT (0.40) ALPLCA12RPA1HDAC3HDAC4
SCHEMBL18558584 0.93 MAPT (0.44) ALPLHDAC3HDAC4HDAC1HDAC7
SCHEMBL18558233 0.92 MAPK1 (0.38) ALPLCA12RPA1HDAC3HDAC4
SCHEMBL18558217 0.92 ALPL (0.39) ALPLCA12RPA1HDAC3HDAC4
SCHEMBL19362634 0.91 CA2 (0.39) ALPLCA12RPA1HDAC3HDAC4
SCHEMBL18558161 0.91 ALPL (0.40) ALPLCA12RPA1HDAC3HDAC4
SCHEMBL17089807 0.91 HDAC3 (0.36) ALPLCA12RPA1HDAC3HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9932313-B2 Pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2018-04-03 US disclosed
US-20170267643-A1 PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF WILMINGTON TRUST, NATIONAL ASSOCIATION 2017-09-21 US disclosed
US-9580388-B2 Pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2017-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170267643-A1 PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF ATP5F1A, ATP5F1D, ATP5ME ALPL 4028/4885CA12 4881/4885RPA1 1520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.